CellPly
Cellply is a deep tech company based in Italy that develops advanced analytical tools to accelerate the development of next-generation cancer cell therapies. Their flagship product, the VivaCyte platform, offers a unique, fully automated system for high-throughput characterization of immune cells at single-cell resolution, supporting biopharma companies and research institutes from discovery through R&D to quality control of advanced therapies. The platform enables analysis of over 100 samples per run and more than 1,000 single cells per sample, providing unprecedented resolution and scale. Cellply's technology integrates microfluidics, robotics, AI, biology, and immunology to streamline cancer immunotherapy development and is adopted globally by leading biopharma companies and research institutions. The company has strategic partnerships, including with Eurofins Biopharma Product Testing (BPT) Italy, enhancing access to their platform for cellular therapy developers.
CellPly
Cellply is a deep tech company based in Italy that develops advanced analytical tools to accelerate the development of next-generation cancer cell therapies. Their flagship product, the VivaCyte platform, offers a unique, fully automated system for high-throughput characterization of immune cells at single-cell resolution, supporting biopharma companies and research institutes from discovery through R&D to quality control of advanced therapies. The platform enables analysis of over 100 samples per run and more than 1,000 single cells per sample, providing unprecedented resolution and scale. Cellply's technology integrates microfluidics, robotics, AI, biology, and immunology to streamline cancer immunotherapy development and is adopted globally by leading biopharma companies and research institutions. The company has strategic partnerships, including with Eurofins Biopharma Product Testing (BPT) Italy, enhancing access to their platform for cellular therapy developers.